Health & Life Sciences

After studying economics at RWTH Aachen University of Cologne, Werner Baumann began his career at Bayer in 1988. He joined the Board of Management in 2010 as hief Financial Officer. From October 2014 until his appointment as Chairman of the Board of Management, he served as Chief Strategy and Portfolio Officer. On May 1, 2016, Werner Baumann became Chairman of the Board of Management (CEO) of Bayer AG.

Sir Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension, which has discovered over 1000 gene loci for blood pressure. He served on the NICE Guideline Group for hypertension and was President of the British Hypertension Society (2009-2011).
He was Director of the William Harvey Research Institute between 2002 and 2020 and was elected a Fellow of the Academy of Medical Sciences in 2008. Since 2008 he directs the National Institute for Health Research Cardiovascular Biomedical Research Unit and Centre at Barts. Between 2010 and 2015 he co-led the merger of three hospitals in North London to create the new £400 million Barts Heart Centre. He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018. In 2013 he became an NIHR Senior Investigator and was appointed as the Chief Scientist for Genomics England (100,000 Genomes Project. Sir Mark was awarded a Knighthood in the June 2019 Queen’s Birthday Honours List for services to the 100,000 Genomes Project.

Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer of Medtronic, the world’s leading medical technology company, with more than 90,000 employees and operations reaching more than 150 countries. Medtronic offers technologies and solutions to treat a wide range of medical conditions, including cardiac and vascular diseases, respiratory, neurological and spinal conditions, diabetes, and more.
Prior to his role as Chairman and CEO, Geoff held an array of global leadership positions at Medtronic, including President, leading Medtronic’s operating groups and regions. He served as EVP and President of Medtronic’s Restorative Therapies Group (RTG), where he had global responsibility for RTG’s four divisions. Geoff also served as SVP of Strategy and Business Development, leading the $10 billion acquisition and integration of Covidien — the largest medical technology acquisition in the history of the industry. An ardent supporter of philanthropic and diversity initiatives, Geoff is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics. He serves on the board of directors for Children’s HeartLink and the Northside Achievement Zone. Geoff also serves on the Development Council for Penn State’s College of Liberal Arts. Prior to joining Medtronic, Geoff held several leadership positions in his 19-year career with GE, including the role of Managing Director of Business Development at GE Healthcare and several roles with GE Capital. He received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University, where he graduated with highest honors.

Leon was appointed Executive Vice-President, Asia Pacific in January 2017 and assumed responsibility for the growth and performance of AstraZeneca’s commercial businesses in all our International markets in April. These markets include China, Asia Area, Australia & New Zealand as well as Latin America and Brazil, Russia and Eurasia and the Middle East and Africa. Leon joined AstraZeneca China in 2013 as a Vice-President and became President in 2014. Under his leadership China became AstraZeneca’s second-largest market worldwide. Leon has twenty years of experience in the pharmaceutical industry, including a series of positions of increasing responsibility in marketing and business leadership at Roche where he was a Business Unit Vice-President. He is Council Vice Chairman of the Shanghai Association of Foreign Investment, Executive Committee Member responsible for Pricing of the R&D based Pharmaceutical Association Committee under the China Association of Enterprises with Foreign Investment, Corporate Advisory Board Member of China Europe International Business School and guest lecturer at Shanghai International Studies University. He holds a Bachelor of Arts from Shanghai International Studies University and an EMBA from China Europe International Business School.